Marginum is a Finland-based medical technology startup founded in 2020. The company focuses on developing fluorescence-based tissue detection systems for monitoring tumor tissues during cancer surgery. Its data-driven solutions aim to ensure the safe and efficient detection of tumor tissues without disrupting existing surgical workflows. The products, derived from cutting-edge research, are designed to enhance surgical performance and cost-effectiveness. Marginum collaborates closely with academic, clinical, and industrial experts to guarantee the seamless clinical compatibility of its technological solutions.
In November 10, 2023, Marginum secured a €1.00M Seed Round investment from notable investors including Redstone, Restone Capital, Almaral, and Nostetta Ventures. This investment is a testament to the potential of Marginum's innovative approach and the confidence that these prominent investors have in the company's vision and solutions within the Health Care and Medical Devices industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €1.00M | 4 |
|
10 Nov 2023 |
| Debt Financing | €700.00K | 1 |
|
10 Nov 2023 |
| Pre Seed Round | €150.00K | 1 | Nostetta Ventures | 31 Dec 2021 |
No recent news or press coverage available for Marginum.
We care about your data, and we'd love to use cookies make your experience better.
